

ASX Release

Anatara Investor Presentation

BRISBANE & MELBOURNE, 23rd October 2019: Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will present today at the 10th Annual Australian Microcap Investment Conference, held in Melbourne, VIC.

A copy of the presentation is attached.

For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anatara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anatara.com	Sue MacLeman Chair, Anatara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anatara.com

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.



Australian Microcap Investment Conference October 2019



Advancing gastrointestinal health

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor.

Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk.

Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation.

Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Key Investor Message

More than ever, the world is looking for safe and effective solutions to gut health.

The Anatará team is focussed on delivering evidence-based, commercially attractive solutions for gastrointestinal diseases in animals and humans.



Corporate Fast Facts



ASX ticker code

ANR

Share Price

\$0.22*

Market Capitalisation

\$10.87 million*

Ordinary Shares

49,413,236

Options

2,571,000

Board of Directors:

Sue MacLeman

Dr Jane Ryan

Dr Tracie Ramsdale

Dr David Brookes

Management:

Steve Lydeamore, CEO

Dr Tracey Brown, CSO

Dr Michael West, COO

Product Development

Advisory Board:

Prof Peter Gibson

Dr Rebecca Burgell

Dr Jakob Begun

Laureate Prof Nick Talley

Prof Jane Andrews

Prof Barry Campbell

Assoc Prof Simon Keely

Investment highlights: multiple shots on goal

Human health asset, GaRP:

- Aimed at restoring and maintaining **gut health** with excellent (pre-clinical *in vitro* and *in vivo* animal studies) data to date
- **Human clinical study** initiation anticipated late 2019
- View to a **partnering deal** by 2H 2020

Animal health asset, Detach[®]:

- Asset developed for control of scour in piglets
- Well positioned in the livestock market which is in urgent need of non-antibiotic solutions
- Targeting international animal health partner(s) to license and commercialise Detach[®] by end FY 2020

Need to combat antimicrobial resistance

“Antimicrobial resistance is one of the most urgent health risks of our time and threatens to undo a century of medical progress.”

Dr Tedros Ghebreyesus, Director-General, World Health Organisation (WHO) 2019

70% of bacteria globally has developed some level of resistance to antibiotics¹

10 million: the number of people who could die every year due to AMR by 2050²

70% of antibiotics are used for food animal production³

>70% US consumers believe antibiotic-free meat benefits their own health⁴

Detach[®] can help

Detach[®] increases survivability and provides health benefits to pre-weaning piglets

- 15-20%⁵ of piglets born will die before weaning due to health issues including **scour**
- Orally administered, non-antibiotic product for the **control of scour** in piglets
- **Natural product** extracted from pineapple stems
- Unlike antibiotics and zinc oxide, Detach[®] is **unlikely to contribute to antimicrobial resistance**

Detach[®] Next Steps


- Secure international animal health partner(s)
 - by end **FY 2020**
 - regulatory approval of Detach[®] in key **overseas markets**
 - opportunity to fast track registration in SE Asia
 - develop **new formulations** and administration methods for Detach[®] to expand utility
 - develop Detach[®] for **other livestock species**, such as poultry





From animals to humans

Burgeoning microbiome market: our first targets



IBS and IBD in a minute



11%

IBS affects around 11% of the global population⁶



> 5m

With accelerating incidence, IBD has an estimated >5million sufferers worldwide⁷



IBS costs more than **\$21 billion** annually in direct medical costs and absenteeism⁸



Total financial burden of IBD in the US alone was estimated to be **\$15-32 billion** in 2014⁹



IBS patients have a **poor quality of life** and **use healthcare system more than other patients**



IBD treatment involves **suppressing inflammation** with the goal of inducing and maintaining remission



Patients experience **symptoms** such as **pain, bloating and diarrhoea**



Up to **50%** of IBS/IBD patients turn to dietary supplements, complementary and alternative medicines^{10, 11}

Profound impact on patients

*"Imagine a day where you fell ill from having eaten too much, then imagine that day lasts **months at a time.**"*

Australian IBS patient¹²

Why a dietary supplement*?

The advantages of a dietary supplement regulatory strategy are:

Fewer or lower regulatory requirements than pharmaceuticals¹³

- **Lower development cost**
- **Lower development risk**
- **Faster time to market**

Swift timeframe to partnering milestone

Rapid market penetration¹⁴



* Dietary Supplements are foods intended to supplement the normal diet which are concentrated sources of one or more nutrients, like vitamins, proteins, mineral complexes, herb or other botanical, amino acid or enzymes.

USA gastrointestinal health market

US \$8b

USA digestive remedies and GI supplement sales



8/10

Adults suffer annually from a digestive issue¹⁵



US\$5b

OTC** digestive remedies 2018¹⁵



US\$3b

GI* supplement sales 2018¹⁶



↑ 11.9%

OTC** digestive remedies over the past 5 years¹⁵

* GI = Gastrointestinal

** OTC = over-the-counter

Global consumer health market opportunity

US\$5.7 billion

Global probiotic supplement sales¹⁷

Probiotic supplements



Align® (P&G) sales
(U.S.) 2018:
US\$171.9m¹⁷

Other GI supplements



Iberogast® (Bayer) sales
(Germany) 2018:
US\$145m¹⁷


OTC digestive supplements




Buscopan® (Sanofi) sales
(Global) 2018:
US\$220m¹⁸

(OTC only, excludes prescription sales)

3 primary underlying factors of IBS and IBD



How are these addressed?




***G**astrointestinal **R**eProgramming (**GaRP**) dietary supplement


Changing the game for IBS and IBD

GaRP dietary supplement

- Regenerative, multi-component dietary supplement
- Triple-targeted therapeutic approach
 - *anti-adhesion*
 - *anti-inflammatory*
 - *mucosal regeneration*
- Dual targeted formulation, delivering components to where they can be most effective



Grounded in scientific evidence



Successful Proof of Concept Studies (February & October 2019)
 Demonstrated using industry-standard *in vitro* gut model

GaRP has been shown to.....

- **Address the dysbiosis of the microbiome**
 - Inhibiting the attachment and invasion of pro-inflammatory bacteria by **>95%**
- **Reduce gut inflammation**
 - Reducing the production of pro-inflammatory proteins by **>85%**
 - Reducing colon inflammation and disrupted bowel habits by **2.5-fold** in mice
 - Potential to reduce immunosuppressive dosing in IBD when GaRP used as an adjunct to prescription immunosuppressants
- **Promote mucosal healing**
 - Upregulating the expression of mucin genes (MUC2 & MUC6) that are normally downregulated in both IBD and IBS
 - Increasing the expression of mucin genes by a factor of **5 to 7-fold** (MUC2 and MUC6 genes)

Anticipated Milestones

- Further data from preclinical *in vivo* **animal studies** is expected **late 2019**
- Pre-trial activities for a **human clinical study** in IBS patients have commenced, with a view to study initiation **late 2019**
- Anantara is exploring options to build marketing capability and pipeline for selected markets
- Detach[®] partnering deal by **end FY 2020**
- GaRP **partnering** deal by **2H 2020**





Contact Anatará Lifesciences Ltd

Steven Lydeamore, CEO

+61 438 027 172

slydeamore@anatará.com

www.anatarálifesciences.com

@AnataráANR



anatará-lifesciences-ltd

